Lechleider Robert sold $1.1M of IMNM
Lechleider Robert (Chief Medical Officer) sold 55,000 shares of Immunome Inc. (IMNM) at an average of $19.85 ($19.56–$20.66, $1.09M total) across 2 trades on 2026-06-25 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the CMO’s $1.09M open-market sale (55,000 shares) on 2026-06-25, filed 2026-06-29, under a 10b5-1 plan.
Market read
Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a major repricing without additional company catalysts.
What to watch
The filing does not disclose any new clinical, regulatory, or financial information—so traders should avoid extrapolating fundamentals from the sale alone.
Background
The article is an SEC Form 4 insider transaction disclosure for Immunome Inc. (IMNM).
Ticker impact
Immunome CMO Robert Lechleider sold ~$1.09M of IMNM shares via an open-market sale under a pre-arranged 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely muted and short-lived unless paired with other news.
The filing is a routine Form 4 insider transaction with a stated 10b5-1 plan and no accompanying operational/regulatory/financial catalyst in the text.
Market effects
Minimal; single-company insider sale without sector-wide signal.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.
Key entities
- issuerImmunome Inc.
Subject of the Form 4 insider transaction; CMO sold shares under a 10b5-1 plan.
- insiderLechleider Robert
Chief Medical Officer who executed the open-market sale.